CRISPR Therap

Forecast & Rating22 analysts currently cover CRISPR Therap, with about 59.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $87.56, about 54.8% upside from the current price of $56.56. Price targets range from $44.00 to $291.00 — a wide spread, showing clear disagreement over just how much CRISPR Therap can rise. Historically, about 34.5% of past price targets were eventually met, which adds credibility. For you, this means institutional views on CRISPR Therap are split — bulls and bears coexist, so you'll need to weigh it against your own judgment. Data as of Sep 9, 2026; for reference only and not investment advice.